Patient with EGFR-mutated NSCLC develops brain metastases after first-line EGFR inhibitor and chemotherapy

Dr. Sands presented a case of a patient with metastatic non-small cell lung cancer that carries an EGFR mutation.

The patient was treated with a first-line regimen that combined an EGFR tyrosine kinase inhibitor and chemotherapy.

Despite this approach, the disease progressed and new brain metastases were identified.

The case underscores the difficulty of managing EGFR-mutated NSCLC when resistance emerges after combination therapy.